Section Arrow
Quote
UTHR.NASDAQ
- United Therapeutics Corp
Quotes are at least 15-min delayed:2025/05/10 16:58 EDT
Last
 301.42
-6.58 (-2.14%)
Day High 
313.35 
Prev. Close
308 
1-M High
319.4 
Volume 
335.34K 
Bid
279
Ask
326
Day Low
301.23 
Open
308.26 
1-M Low
266.98 
Market Cap 
13.89B 
Currency USD 
P/E 12.27 
%Yield -- 
10-SMA 298.94 
20-SMA 292.77 
50-SMA 302.61 
52-W High 417.815 
52-W Low 263.56 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
25.10/29.21
Enterprise Value
14.19B
Balance Sheet
Book Value Per Share
150.91
Cash Flow
Cash Flow Yield
0.10
Income Statement
Total Revenue
2.88B
Operating Revenue Per Share
48.87
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SHPHShuttle Pharmaceuticals Holdings Inc0.2325-0.0375-13.89%-- 
PTPIPetros Pharmaceuticals Inc0.1201-0.0053-4.23%-- 
VTRSViatris8.77-0.32-3.52%227.2PE
TEVATeva Pharmaceutical Industries Limited16.93-1.14-6.31%-- 
IXHLIncannex Healthcare0.1135+0.0009+0.80%-- 
Quotes are at least 15-min delayed：2025/05/10 16:58 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.